The efficacy and safety of targeted therapy with or without chemotherapy in advanced gastric cancer treatment: a network meta-analysis of well-designed randomized controlled trials

Tingting Zhao(Sun Yat-sen University), Zhi‐Feng Miao(Kaohsiung Medical University), Yingying Xu(Wannan Medical College), Huimian Xu(First Hospital of China Medical University), Xingyu Liu(Tongji Hospital), Yongxi Song(First Hospital of China Medical University), Hao Xu(China Medical University), Songcheng Yin(Sun Yat-sen University)

Gastric Cancer

February 17, 2018

10.1007/s10120-018-0813-2

Cited by 67

Related Papers

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021

|Cancer Communications|2021|657

Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial

|The Lancet Oncology|2021|436

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023

|癌症：英文版|2023|412

Biomarkers of aging

|Science China Life Sciences|2023|362

Microenvironment-Responsive Metal-Phenolic Nanozyme Release Platform with Antibacterial, ROS Scavenging, and Osteogenesis for Periodontitis

|ACS Nano|2023|345